

Interview Summary

Application No.
09/717,095

Applicant(s)
Vinik et al.

Examiner
HOPE ROBINSON

Art Unit
1653



All participants (applicant, applicant's representative, PTO personnel):

(1) Hope Robinson

(3) Sarah Kagan

(2) Karen Carlson

(4) _____

Date of Interview Jun 21, 2002

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy is given to 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No. If yes, brief description:

Claim(s) discussed: 12, 17, 19, and 24

Identification of prior art discussed:

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Ms. Kagan agreed to the proposed language suggested by Primary Examiner Carlson (see the attached examiner's amendment). Ms. Kagan will provide a Terminal Disclaimer for the above application.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☒ It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Art Unit: 1653

Proposed Claims:

The claims have been amended as follows:

(a) Claim 12 (Twice Amended) An isolated DNA molecule comprising at least 30 contiguous nucleotides of a sequence encoding a mammalian islet cell neogenesis associated protein (INGAP), wherein said protein has the sequence shown in SEQ ID NO:2, wherein said DNA encodes a polypeptide which stimulates islet cell neogenesis.

(b) Claim 17 (Twice Amended) An antisense construct of a mammalian islet cell neogenesis associated protein (INGAP) gene comprising:
a promoter, a terminator, and a nucleotide sequence which encodes all or a portion of a protein as shown in SEQ ID NO:2, said nucleotide sequence being between said promoter and said terminator, said nucleotide sequence being inverted with respect to said promoter, whereby upon expression from said promoter an mRNA complementary to native mammalian INGAP mRNA is produced, wherein the complementary mRNA prevents translation of the native mammalian INGAP mRNA.

(c) Claim 24 (Amended) The DNA molecule of claim 12 which encodes a portion of INGAP, wherein said DNA encodes a polypeptide which stimulates islet cell neogenesis.
